Avita Medical
1st Floor, Unex House
132-134 Hills Road
Cambridge
CB2 8PA
United Kingdom
Tel: 44-0-1223 341150
Fax: 44-0-1223-341170
Website: http://www.avitamedical.com/
Email: info.eu@avitamedical.com
274 articles about Avita Medical
-
AVITA Medical Appoints Interim CFO
5/15/2019
AVITA Medica announced that Dale A. Sander is resigning as Chief Financial Officer (CFO) to spend more time with his family on the east coast, effective immediately.
-
AVITA Medical to Present at RBC Capital Markets 2019 Healthcare Conference
5/2/2019
AVITA Medical, a global regenerative medicine company, announced that management will present at the RBC Capital Markets 2019 Healthcare Conference in New York.
-
AVITA Medical Third Quarter Fiscal 2019 Quarterly Cash Flow Report and Company Update
4/30/2019
Strong U.S. product sales of A$2.2 million for third quarter of Fiscal 2019 were double second quarter sales
-
In September 2018 a leap forward in treating burn victims was made with the approval of Avita Medical's RECELL Autologous Cell Harvesting Device. The Food and Drug Administration (FDA) green lit the California-based company’s burn treatment device that uses a small amount of a patient’s own skin...
-
AVITA Medical Announces Presentation at ABA Meeting Highlighting Results of Study Using RECELL® System to Treat Third-Degree Burns in Pediatric Patients
4/8/2019
Professor Fiona Wood, co-inventor of the RECELL System, described her experience treating more than 3,500 patients using RECELL and resulting benefits, including reduced time to healing and decreased length of hospitalization
-
AVITA Medical RECELL® System Health Economic Data Project USD $28 Million in Annual Savings at a Single Major Burn Center Versus Standard of Care
4/5/2019
Additional data presented at ABA Annual meeting include results demonstrating that donor sites treated using the RECELL System could be reharvested in as little as seven days after treatment
-
AVITA Medical to Present at Cowen and Company Health Care Conference
3/12/2019
AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that management will present at the Cowen and Company 39th Annual Health Care Conference in Boston.
-
AVITA Medical Announces Ten RECELL® System Presentations at the American Burn Association (ABA) Annual Meeting
3/11/2019
Presentation describing treatment of pediatric patients with RECELL System selected as “Best of the Best Abstract”
-
Avita Medical Announces Collaboration with COSMOTEC, an M3 Group Company, to Commercialize the RECELL® System in Japan
3/4/2019
COSMOTEC has filed a JPMDA application for approval to market the RECELL System in Japan
-
AVITA Medical Announces Temporary Interruption of Sales of Products in EU
3/3/2019
Sales temporarily interrupted while closing administrative and procedural open items related to EU certificates and unrelated to product performance
-
Avita Medical Half-Year Financial Report for Fiscal 2019
2/28/2019
AVITA Medical, a global regenerative medicine company, announced that it filed with the ASX its Appendix 4D – Half-Year Report for the six months ended 31 December 2018.
-
Avita Medical Second Quarter Fiscal 2019 Quarterly Cash Flow Report and Company Update
1/31/2019
Pre-launch U.S. product sales of A$1.1 million in second quarter
-
AVITA Medical Announces Nine RECELL® System Abstracts Accepted for Presentation at American Burn Association (ABA) 51st Annual Meeting
1/28/2019
RECELL System clinical benefits and cost savings featured in 26 presentations at four burn conferences in early 2019
-
AVITA Medical Announces U.S. National Market Launch of RECELL® System
1/8/2019
Strong market response to the RECELL System approval in advance of U.S. launch with 36 burn centers actively reviewing the product or placing commercial orders
-
AVITA Medical Named One of the Most Innovative Companies of 2018 by PM360
12/20/2018
AVITA Medical today announced that PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named AVITA as one of the most innovative companies of 2018.
-
AVITA Medical Announces Receipt of A$1.4 Million Research and Development Tax Credit
12/18/2018
AVITA Medical today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office in the amount of A$1,421,000 for the year ending 30 June 2018.
-
AVITA Medical Announces Hiring of Full U.S. Sales Team of Experienced Burn Professionals to Support National Launch of RECELL® System
11/16/2018
Strong market response to the RECELL System approval in advance of U.S. launch with 32 burn centers actively reviewing the product or placing commercial orders
-
Leading Burn Surgeons Present Positive RECELL® System Results at 31st Annual Southern Region Burn CME Conference and Northeast Region Burn Conference
11/13/2018
Burn surgeon presents health economic model projecting burn center will save up to USD $21 million per year treating patients with the RECELL System compared to conventional treatment
-
Avita Medical First Quarter Fiscal 2019 Quarterly Cash Flow Report and Company Update
10/31/2018
FDA approval of RECELL® System for the treatment of acute thermal burns in adults
-
AVITA Medical Announces Commencement of Randomized Controlled Clinical Study of RECELL® System in Treatment of Children with Burn Injuries
10/25/2018
Clinical study is being conducted in Brisbane, Australia, in collaboration with the Queensland University of Technology and Lady Cilento Children’s Hospital